AIFA grants reimbursement to SIFI’s Iluvien

SIFI announced that Iluvien (fluocinolone acetonide), a product for the treatment of Diabetic Macular Edema, has been granted reimbursement by the Italian Medicines Agency (AIFA). SIFI exclusively markets Iluvien in Italy, San Marino and Vatican City under license from Alimera Sciences. The product, already granted approval in Europe and the United States, is an innovative intravitreal implant, which provides a sustained and continuous drug release. The condition it targets – diabetic macular edema – is a disabling eye disease triggering a progressive reduction of vision, which can lead to blindness. AIFA has granted full reimbursement for the product and use as a hospital treatment in patients who have previously undergone cataract surgery. (Source SIFI press release)